Skip to main content
Home / Current Pharmaceutical Design, Volume 18, Number 25
Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Publisher: Bentham Science Publishers

More about this publication?
Volume 18, Number 25, 2012

Articles

Editorial: [Hot Topics: The Blood Brain Barrier in Stroke]
pp. 3613-3614(2)
Author: V. Borlongan, Cesar

Favourites:
ADD

Breaking the Barrier in Stroke: What Should we Know? A Mini-Review
pp. 3615-3623(9)
Authors: V. Borlongan, Cesar; A. Rodrigues, Antonio; Carolina Oliveira, Maria

Favourites:
ADD

Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
pp. 3624-3644(21)
Authors: T. Ronaldson, Patrick; P. Davis, Thomas

Favourites:
ADD

Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier
pp. 3645-3648(4)
Authors: Hae Seo, Ji; Guo, Shuzhen; Lok, Josephine; Navaratna, Deepti; J. Whalen, Michael; Kim, Kyu-Won; H. Lo, Eng

Favourites:
ADD

Mechanisms of Endogenous Endothelial Repair in Stroke
pp. 3649-3652(4)
Authors: Yamashita, Toru; Abe, Koji

Favourites:
ADD

The Role of Pericytes in Blood-Brain Barrier Function and Stroke
pp. 3653-3662(10)
Authors: Liu, Shuo; Agalliu, Dritan; Yu, Chuanhui; Fisher, Mark

Favourites:
ADD

Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
pp. 3663-3669(7)
Authors: Tajiri, Naoki; Lau, Tsz; E. Glover, Loren; Shinozuka, Kazutaka; Kaneko, Yuji; van Loveren, Harry; V. Borlongan, Cesar

Favourites:
ADD

Permeating the Blood Brain Barrier and Abrogating the Inflammation in Stroke: Implications for Stroke Therapy
pp. 3670-3676(7)
Authors: V. Borlongan, Cesar; E. Glover, Loren; R. Sanberg, P.; C. Hess, David

Favourites:
ADD

Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke
pp. 3677-3684(8)
Authors: Ishrat, Tauheed; Soliman, Sahar; Guan, Weihua; Saler, Mihaela; C. Fagan, Susan

Favourites:
ADD

Tracking Stem Cells for Cellular Therapy in Stroke
pp. 3685-3693(9)
Authors: C. Manley, Nathan; K. Steinberg, Gary

Favourites:
ADD

A Series of Novel Neuroprotective Blood Brain Barrier Penetrating Flavonoid Drugs to Treat Acute Ischemic Stroke
pp. 3694-3703(10)
Author: A. Lapchak, Paul

Favourites:
ADD

Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
pp. 3704-3720(17)
Authors: Hu, Xiaoming; Zhang, Meijuan; K Leak, Rehana; Gan, Yu; Li, Peiying; Gao, Yanqin; Chen, Jun

Favourites:
ADD

CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
pp. 3721-3730(10)
Author: Cho, Sunghee

Favourites:
ADD

Cell Therapy for Stroke: Emphasis on Optimizing Safety and Efficacy Profile of Endothelial Progenitor Cells
pp. 3731-3734(4)
Authors: Kaneko, Yuji; Tajiri, Naoki; Shinozuka, Kazutaka; E. Glover, Loren; L. Weinbren, Nathan; Cortes, Lourdes; V. Borlongan, Cesar

Favourites:
ADD

Editorial: Advances in Epithelial Ovarian Cancer Therapy
pp. 3735-3740(6)
Author: R. Kroep, Judith

Favourites:
ADD

Review of Dose-intense Platinum and/or Paclitaxel Containing Chemotherapy in Advanced and Recurrent Epithelial Ovarian Cancer
pp. 3741-3753(13)
Authors: A. Boere, Ingrid; E.L. van der Burg, Maria

Favourites:
ADD

Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
pp. 3754-3769(16)
Authors: J. Monk, Bradley; Dalton, Heather; Benjamin, Ivor; Tanovic, Adnan

Favourites:
ADD

The Role of PARP Inhibitors in the Treatment of Ovarian Carcinomas
pp. 3770-3774(5)
Authors: V. Tinker, Anna; Gelmon, Karen

Favourites:
ADD

The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer
pp. 3775-3783(9)
Authors: R. Kroep, Judith; W.R. Nortier, Johan

Favourites:
ADD

Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance
pp. 3784-3792(9)
Authors: R.M. van der Bilt, Arne; G.J. van der Zee, Ate; G.E. de Vries, Elisabeth; de Jong, Steven; Timmer- Bosscha, Hetty; A. ten Hoor, Klaske; F.A. den Dunnen, Wilfred; Hollema, Harry; K.L. Reyners, Anna

Favourites:
ADD

Survival Benefit of Adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the Different Time-points of Treatment of Ovarian Cancer: Review of Evidence
pp. 3793-3803(11)
Authors: Mulier, Stefaan; Claes, Jean-Pierre; Dierieck, Vincent; Amiel, Jean-Olivier; Pahaut, Jean-Philippe; Marcelis, Luc; Bastin, Fabienne; Vanderbeeken, Denis; Finet, Claude; Cran, Sophie; Velu, Thierry

Favourites:
ADD

Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
pp. 3804-3811(8)
Authors: Vermeij, Renee; Leffers, Ninke; J. Melief, Cornelis; Daemen, Toos; W. Nijman, Hans

Favourites:
ADD

Role of Farletuzumab in Epithelial Ovarian Carcinoma
pp. 3812-3815(4)
Authors: Jelovac, Danijela; K. Armstrong, Deborah

Favourites:
ADD

Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
pp. 3816-3827(12)
Authors: M. Dijkgraaf, Eveline; J.P. Welters, Marij; W.R. Nortier, Johan; H. van der Burg, Sjoerd; R. Kroep, Judith

Favourites:
ADD

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content